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Endometriosis, a major reproductive pathology affecting 8–10% of women is characterized by chronic 
inflammation and immune dysfunction. Human antigen R (HuR) and Tristetraprolin (TTP) are RNA 
binding proteins that competitively bind to cytokines involved in inflammation including: tumor 
necrosis factor alpha (TNF-α), granulocyte macrophage colony stimulating factor (GM-CSF), interleukin 
6 (IL-6) among others, and stabilize and destabilize them, respectively. The aim of this study was to 
examine RNA binding protein (RNABP) HuR/TTP axis in endometriosis patients compared to menstrual 
stage matched healthy fertile controls in hopes of better understanding their contribution to the 
pathogenesis of endometriosis. Additionally, using a targeted in vitro siRNA approach, we examined 
whether knock-down of TTP can play a functional role on other RNABPs that competitively bind to 
inflammatory targets of TTP in both endometriotic and endometrial epithelial cell lines. Our results 
suggest that RNABPs TTP and HuR are dysregulated in endometriotic lesions compared to matched 
eutopic patient samples as well endometrium from healthy controls. Silencing of TTP in endometriotic 
and endometrial epithelial cells revealed differential response to inflammatory cytokines and other 
RNABPs. Our results suggest potential involvement of HuR/TTP RNA binding protein axis in regulation 
of inflammation in endometriosis.
Endometriosis is a reproductive pathology characterized by growth of endometrium-like tissue outside of the 
uterus in ectopic sites1, 2. It is now well established that chronic inflammatory milieu in the peritoneal cavity of 
endometriosis patients contributes to pain and infertility associated with the disease3. Despite decades of research, 
current treatment option transiently alleviate but do not cure the disease. The most widely accepted Sampson’s 
theory of retrograde menstruation, postulates that endometrial fragments from retrograde menstruation lead 
to endometriosis pathogenesis4. This theory however remains to adequately address why although 78–90% of 
women experience retrograde menstruation, endometriosis only affects 8–10% of all women of reproductive 
age, irrespective of ethnicity2, 5–7. Previous research has shown strong evidence of increased pro-inflammatory 
and decreased anti-inflammatory cytokines in the peritoneal fluid in endometriosis patients8. Indeed, we have 
shown endometriotic lesions are primary drivers of inflammation and surgical removal of lesions leads to tem-
porary decline in the levels of pro-inflammatory cytokines in systemic circulation of endometriosis patients9. 
We have also shown that endometriotic lesions and eutopic endometrium of endometriosis patients have unique 
immune-inflammation gene signatures9. Other work from our lab has shown that IL-17A can contribute to lesion 
development via both promotion of inflammation and stimulating production of angiogenic cytokines10. This 
evidence clearly suggests that inflammation is central to the progression of endometriosis associated pain and 
potential infertility. However, it is not clear whether inflammation contributes to the pathogenesis of endometri-
osis or is a by-product of endometriotic lesion establishment. It is also not clear whether and how inflammation 
is regulated in endometriosis.
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Tristetraprolin (TTP) is an RNA binding protein (RNABP) encoded by ZFP36 in humans (Zfp36 in mice) that 
can bind and destabilize mRNA transcripts of important inflammatory or inflammation-related cytokines includ-
ing: tumor necrosis factor alpha (TNF-α)11, granulocyte macrophage colony stimulating factor (GM-CSF)12, 
cyclooxygenase-2 (COX-2)13, Interleukins IL-1a, IL-2, IL-3, IL-6, IL-10, IL-12 and IL-2314–18. Tristetraprolin 
exerts its destabilizing function via binding to AU-rich element (ARE) regions that reside within the 3′ untrans-
lated region (UTR) of a variety of mRNA transcripts, which ultimately leads to degradation of the target19. The 
TTP or TIS11 family of RNA binding proteins have been previously characterized in normal human tissues and 
all three members were found to be expressed in moderate to high levels in both the ovary and cervix, and thus 
are expressed in physiologically relevant levels throughout the female reproductive tract, including the placenta20. 
Recently, TTP has been identified as a global post-transcriptional regulator of inflammation, signifying its con-
served importance in maintenance of homeostatic balances of cytokine production21.
Human antigen R (HuR), or ELAVL1 is another RNA-binding protein expressed within the reproductive 
tract in humans. This RNA-binding protein has similar functions to TTP; to bind to inflammatory cytokines, 
however its role is opposite to that of TTP, by stabilizing the transcripts of the same cytokines22. HuR thus acts as 
an RNA-stabilizer, while TTP acts as a RNA-destabilizing factor. Human antigen R has been previously reported 
to be important for early placental and embryonic development23. Previous work from our group has shown that 
all three members of the TTP gene family are expressed and are biologically relevant at the maternal-interface 
in a fetal loss model in pigs24. Our group has also shown relevance of RNABPs including TTP and HuR as well 
as localization of TTP in inflammatory conditions using a mouse model of recurrent pregnancy loss25. Other 
RNA binding proteins such as AUF1 have also been shown to have indirect effects by influencing methylation 
under hypoxic conditions in endometriosis26. The adult stem cell marker RNA binding protein, Musashi-1 has 
been shown to be increased in endometriosis and endometrial carcinomas27. Unlike Musashi-1, an RNA binding 
protein involved in programmed cell death, TIA-1 cytotoxic granule-associated RNA binding protein, is down-
regulated in the ectopic endometrium. Additionally, previous work with HuR has shown differential expression 
in ectopic endometriotic lesions compared to eutopic endometrium and that HuR expression varies during the 
menstrual cycle28. However, the mechanisms that might regulate this difference in expression pattern and hormo-
nal effects have yet to be determined.
In this study, we sought to understand whether HuR and TTP family members regulate the inflammatory 
response during endometriotic lesion formation and development. We hypothesized that the HuR/TTP axis 
modulates the inflammatory response at both the site of the endometriotic lesions as well as the local peritoneal 
microenvironment via aberrant expression or dysregulation of these regulators. Our main objectives were to 
determine the in vivo and in vitro associations of TTP and HuR and their selected pro-inflammatory cytokine tar-
gets in matched ectopic and eutopic samples from patients and in healthy fertile controls. Our other objective was 
to characterize the TTP family using a syngeneic mouse model of endometriosis. We also sought to determine the 
mechanisms of HuR/TTP function via in vitro RNA interference/silencing in endometriotic epithelial (12Z) and 
endometrial epithelial carcinoma (EECCs) cells.
Results
ZFP36, ZFP36L1, ZFP36L2 and ELAVL1 mRNA is expressed in endometriosis patient sam-
ples. The mRNA of ZFP36 (encoding TTP), ZFP36L1 (encoding Tis11b), ZFP36L2 (encoding Tis11d) and 
ELAVL1 (encoding HuR) were expressed in matched ectopic lesion and eutopic endometrium from endometrio-
sis patients, as well as in endometrial samples from menstrual stage matched fertile subjects with no evidence of 
endometriosis. The mRNA of ZFP36L1 in eutopic endometrium and ectopic endometriotic lesions was signifi-
cantly lower than in endometrial tissue from controls (Fig. 1 Panel B; p < 0.05). The same was also observed with 
ELAVL1 (Fig. 1 Panel C; p < 0.05). Significantly lower mRNA of ZFP36L2 in eutopic endometrium from patients 
was observed compared to normal healthy endometrium (Fig. 1 Panel D; p < 0.05).
HuR and TTP protein is differentially expressed in endometriosis patients compared to endo-
metrial biopsies from healthy controls. Human antigen R and TTP protein expression were evaluated in 
endometriosis patients and control subjects using enzyme linked immunosorbent assay (ELISA) as well as west-
ern blotting. Significantly higher HuR protein was detected in both matched ectopic and eutopic endometrium 
from patients compared to normal control endometrium from women with no evidence of endometriosis (Fig. 2 
Panel A; p < 0.05). Additionally, significantly higher HuR protein was detected in eutopic endometrium com-
pared to ectopic endometriotic tissues from patients (Fig. 2 Panel A; p < 0.05). Expression of TTP was similar to 
HuR, however to a much lesser extent. TTP was significantly downregulated in normal endometrium compared 
to ectopic and eutopic endometrium from endometriosis patients (Fig. 2 Panel B; p < 0.05). In order to further 
support our ELISA findings, western blots were performed in a different cohort of patients with endometriosis 
(The Ottawa Hospital, Ottawa, Canada), for both HuR and TTP. Bands were detected in both eutopic and ectopic 
endometrium at 36 kDa for HuR and 44 kDa for TTP, matching the predicted molecular weight for each protein 
(Fig. 2 Panels C,D). Significantly higher amounts of HuR and TTP in eutopic endometrium compared to matched 
ectopic endometriotic tissue was also detected using western blotting (Fig. 2 Panel C & D; p < 0.01 & p < 0.05, 
respectively). Overall, less TTP protein was detected in endometrium (in both patients and controls) compared 
to HuR (TTP; approximately 100–180 pg/ml, HuR; 250–700 pg/ml).
Distinct profile of inflammatory cytokine targets in endometriosis patients compared to con-
trols. Of 12 cytokines assessed (GM-CSF, IFNγ, IL-1β, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17, IL-23, 
TNF-α), 5 cytokines involved in inflammation were found to be significantly different in patients compared 
to controls. Significantly higher GM-CSF protein was detected in eutopic compared to matched ectopic endo-
metrium in endometriosis patients (Fig. 3 Panel A; p < 0.05). Additionally, significantly higher GM-CSF was 
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detected in eutopic endometrium from patients with endometriosis compared to endometrium from normal fer-
tile controls (Fig. 3 Panel A; p < 0.05). Whereas Interleukin-10 was significantly higher in eutopic endometrium 
compared to normal fertile controls (Fig. 3 Panel B; p < 0.05). Interleukin-6 was significantly elevated in eutopic 
endometrium compared to ectopic endometriotic lesions from patients (Fig. 3 Panel C; p < 0.05). Interleukin-8 
was significantly elevated in ectopic endometriotic lesions compared to both its matched eutopic endometrium 
as well as in normal fertile endometrium (Fig. 3 Panel D; p < 0.05). Additionally, IL-23 protein had tendency to 
be lower in eutopic endometrium from patients with endometriosis compared to normal fertile controls (Fig. 3 
Panel E; p = 0.098). TTP’s major target, TNF-α was significantly lower in ectopic endometriotic lesions compared 
to normal fertile endometrium (Fig. 3 Panel F; p < 0.05).
Zfp36, Zfp36l1, Zfp36l2 and Elavl1 mRNA is expressed in both ectopic and eutopic endome-
trium in a mouse model of endometriosis. In order to examine if HuR/TTP axis contributes to the 
pathophysiology of endometriosis, we evaluated expression of Zfp36, Zfp36l1, Zfp36l2 and Elavl1 in eutopic and 
ectopic lesions obtained from syngeneic BALB/cByJ mouse model of endometriosis. The RNABP Zfp36 was sig-
nificantly upregulated in ectopic lesions compared to matched eutopic controls (Fig. 4A; p < 0.05). This mRNA 
difference was also observed in Elavl1 (Fig. 4D; p < 0.05), as well as Zfp36l1 (matched test only, Fig. 4C; p < 0.05), 
but not with Zfp36l2 which encodes for Tis11d (Fig. 4E). Dysregulation of HuR/TTP axis in mouse model sup-
ports some of the findings from our endometriosis patient cohorts.
RNABPs are differentially regulated in endometriotic epithelial 12Z cells compared to EECCs 
after silencing of TTP. Knockdown of TTP/ZFP36 in EECCs (Fig. 5A; p < 0.05) resulted in significant 
downregulation of ZFP36L1 as well as ELAVL1 in treated EECC cells compared to scrambled controls (Fig. 5B,D; 
p < 0.05). Although not statistically significant, a trend was observed of lower ZFP36L2 in the treated group com-
pared to controls (Fig. 5C; p = 0.09). On the other hand, knockdown of TTP/ZFP36 in endometriotic 12Z cells 
(Fig. 5E; p < 0.05) resulted in significant upregulation of TTP family member ZFP36L2, and ELAVL1 in treated 
compared to control 12Z cells (Fig. 5G,H; p < 0.05). There was no change in expression for TTP family member, 
ZFP36L1 (Fig. 5F).
Figure 1. HuR/TTP axis mRNA levels are altered in patients with endometriosis: RNA binding protein 
expression profiles in endometriosis patients and in normal fertile controls. mRNA transcripts for ZFP36 
remain unchanged (Panel A). Transcripts for ZFP36L1, ELAVL1 were significantly downregulated in eutopic 
and ectopic endometrium from endometriosis patients when compared to normal endometrium from 
fertile healthy controls (Panels B,C). Transcripts for ZFP36L2 was significantly downregulated in eutopic 
endometrium from patients with endometriosis compared to fertile healthy control women (Panel D). 
Expression data illustrated as mean ± SEM. *P < 0.05. Sample groups consisted of n = 22 human eutopic 
endometrium, n = 22 human ectopic endometriotic lesions, and n = 16 normal control endometrium.
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Inflammatory cytokine mRNAs are differentially regulated in the absence of TTP/ZFP36. In 
order to examine whether TTP interacts with cytokines responsible for inflammation, selected cytokines 
(GM-CSF, IL-6, IL-10, HIF-1α COX-2, TNF-α) associated with inflammation were examined at mRNA level 
in TTP knockdown 12Z and EECCs. Pro-inflammatory cytokine IL-6 was significantly downregulated in TTP 
knockdown EECCs compared to scrambled control (Fig. 6A; p < 0.05). In a similar manner, the pro-inflammatory 
cytokine TNF-a was also significantly downregulated in TTP knockdown EECCs compared to the scrambled 
control (Fig. 5B; p < 0.05). The mRNA for COX-2 (regulator of inflammation) was slightly elevated, although 
not statistically significant (Fig. 6C). The mRNA encoding for HIF-1α was significantly downregulated in TTP 
knockdown EECCs compared to scrambled control (Fig. 6D; p < 0.05). In 12Z cells, transcripts for IL-6 and 
TNF-α did not change (Fig. 6G,H) and COX-2, HIF-1α and GM-CSF were significantly upregulated in TTP 
knockdown cells compared to controls (Fig. 6I,K; p < 0.05).
Analysis of inflammatory cytokines associated with RNABP regulation in the supernatants of 
TTP knockdown endometrial epithelial choriocarcinoma cells (EECCs). Inflammatory cytokine 
protein profiles (GM-CSF, IFN-γ, IL-1B, IL-2, IL-4, IL-6, IL-10, IL-12(p70), MCP-1, TNF-α) were examined in 
the supernatants of TTP knockdown EECCs. In contrast to the downregulated mRNA of TNF-a, significantly 
higher TNF-α protein was detected in TTP knockdown compared to scrambled control (Fig. 7A; p < 0.05). 
Although not statistically significant, a trend was observed of downregulated IFN-γ and GM-CSF in TTP knock-
down EECCs compared to controls (Figs 6F and 7B; p = 0.1).
Figure 2. HuR/TTP axis protein levels are altered in patients with endometriosis: characterization using ELISA 
and western blotting in endometriosis patients and in normal fertile controls. Expression of HuR was significantly 
higher in eutopic endometrium compared to matched ectopic lesions from endometriosis patients as well as 
normal endometrium from healthy controls (Panel A). TTP protein was significantly higher in eutopic and 
ectopic matched endometrium from endometriosis patients compared to normal endometrium from healthy 
controls (Panel B). In a different cohort of women with endometriosis receiving dienogest, HuR and TTP protein 
was significantly higher in matched eutopic endometrium compared to ectopic lesions (Panels C,D, densitometry 
as ratio to ACTB and cropped blots are displayed. Full blot images are shown in Supplemental Figs 1 and 2). 
Expression data illustrated as mean ± SEM. *P < 0.05. Panels A,B (Greenville patient subset) consisted of n = 22 
human eutopic endometrium, n = 22 human ectopic endometriotic lesions, n = 16 normal control endometrium. 
Panels C,D (Ottawa patient subset) consisted of n = 8 human eutopic endometrium and n = 8 human ectopic 
endometriotic lesions.
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Localization of HuR and TTP in both ectopic and eutopic endometrium in a mouse model of 
endometriosis. HuR was localized throughout the tissue microarchitecture of both eutopic and ectopic 
endometrium. Staining was prominent primarily in glandular epithelium, endometrial stroma as well as endo-
metrial epithelium (Fig. 8A and C). HuR immunostaining in the endometrial stroma was primarily cytoplas-
mic, with low to moderate levels of nuclear staining as well in both eutopic and ectopic endometrium. TTP was 
localized primarily in glandular epithelium, endometrial epithelium and luminal epithelium (Fig. 8E compared 
to isotype negative Fig. 8F). High levels of TTP immunolocalization was noted in stromal epithelium in ectopic 
lesions (Fig. 8G compared to isotype negative Fig. 8H).
Discussion
In this study we sought to characterize the HuR/TTP axis in endometriosis with a focus on the inflammatory 
cytokines they have been shown to regulate. We performed initial characterization experiments of HuR/TTP axis 
in our patient cohorts recruited from both USA and Canada. Our group also sought to understand how a disrup-
tion in this axis may influence other RNA binding protein family members as well as their inflammatory targets 
in both endometriotic and non-endometriotic epithelial cell lines. Based on our previous work with RNA binding 
proteins in recurrent pregnancy loss25, we hypothesized that these RNA binding proteins will be differentially 
expressed in endometriosis patients.
At the mRNA level, RNA binding proteins from HuR/TTP axis are expressed in lower quantities in endo-
metriosis patients compared to normal endometrium from healthy fertile women (with exception of ZFP36). 
Transcripts for ZFP36L1 were significantly lower in women with endometriosis in both eutopic endometrium and 
ectopic endometriotic tissues compared to control fertile women. This finding also translated over for ELAVL1 
and to a lesser extent, ZFP36L2, whereby only the eutopic endometrium differed from normal fertile control 
endometrium. These findings are a stark contrast to our protein findings of the HuR/TTP axis. Although to the 
best of our knowledge, no endometriosis-specific characterizations of TTP family have been previously per-
formed, these findings are opposite to those observed in some ovarian cancer cell lines, whereby TTP total mRNA 
transcript copies of the family member ZFP36L1 were elevated when compared to normal ovarian cell line20. 
This suggests to us that there may be different mechanisms at play in endometriosis influence which RNABPs 
compared to cancer pathogenesis.
Our patient ELISA protein expression data of both TTP and HuR reveal differential expression between endo-
metriotic lesions and eutopic endometrium from patients compared to control endometrium from healthy fertile 
Figure 3. Inflammatory cytokine protein profiles in endometriosis patients and compared to normal fertile 
controls. Protein expression using multiplexing reveals higher GM-CSF and IL-10 in eutopic endometrium 
from patients compared to normal endometrium from fertile healthy controls (Panels A,B). Interleukin-6 was 
significantly upregulated in matched eutopic compared to ectopic lesions from patients (Panel C). Similarly, 
Interleukin-8 was upregulated in ectopic endometrium compared to matched eutopic endometrium from 
patients as well as in normal endometrium from healthy fertile controls (Panel D). Tumor necrosis factor 
alpha was higher in normal endometrium from healthy fertile controls compared to ectopic endometrium 
from endometriosis patients (Panel F). Expression data illustrated as mean ± SEM. *P < 0.05. Sample groups 
consisted of n = 22 human eutopic endometrium, n = 22 human ectopic endometriotic lesions, and n = 16 
normal control endometrium.
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Figure 4. Upregulation of HuR/TTP axisRNA binding proteins Zfp36, Zfp36l1, Zfp36l2 (TTP family), and 
Elavl1 (HuR) mRNA in an in vivo mouse model of endometriosis. mRNA transcripts encoding for TTP 
(Zfp36) is elevated in ectopic compared to eutopic endometrium obtained from Balb/c mice (panel A). Zfp36L1 
was elevated in ectopic compared to eutopic endometrium using matched t-test (panel C), however did not 
significantly differ by unpaired student’s t-test (panel B). mRNA expression for Elavl1 and Zfp36l2 was not 
statistically significant (Panel D,E; p = 0.09), and did not differ by paired/matching tests. Endometriosis was 
induced in BALB/cByJ mice by surgical implantation of endometrium isolated from donor mice (n = 2) into 
the left peritoneal cavity of recipient mice. Data presented consists of Days 7 (n = 3) and 17 (n = 3) of eutopic 
endometrium and ectopic lesion harvest. Expression patterns did not change by collection day, however data is 
presented as both time points pooled n = 6. Expression data illustrated as mean ± SEM. *P < 0.05.
Figure 5. TTP knockdown results in endometriotic (12Z) and endometrial epithelial (EECC)-specific effects 
in other RNABPs of HuR/TTP axis: Influence of TTP knockdown on TIS11 family and HuR RNA binding 
proteins in human endometrial epithelial (EECC) and endometriotic (12Z) cells. Transcript ZFP36 which 
encodes for TTP was significantly lower in both EECC and 12Z cells (Panels A,E). Transcripts for ZFP36L1 
and ELAVL1 were also downregulated in EECC cells treated with TTP siRNA (panels B,D). The TTP family 
member ZFP36L2 did not statistically differ upon knockdown of TTP in EECCs (panel C). On the other hand, 
transcripts for ZFP36L2 and ELAVL1 were upregulated in 12Z cells treated with TTP siRNA (panels G,H). 
Transcripts for ZFP36L1 do notstatistically differ when knocked down with TTP siRNA in 12Zs (panel F). 
Expression data illustrated as mean ± SEM. *P < 0.05. Each group (treated and control) consisted of three wells 
performed in triplicates. Data is derived from three independent experiments; n = 3.
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women. This suggests that the downregulation of these RNA binding proteins at the site of the lesion as well as in 
the eutopic endometrium from these patients may in part be linked to the chronic inflammation within the peri-
toneal microenvironment. Indeed, endometriosis patients have elevated level of pro-inflammatory cytokines in 
the peritoneal fluid, blood as well as in the ectopic lesions itself suggesting that endometriotic lesions are probably 
primary drivers of inflammation. We used a different patient cohort that received Dienogest (steroidal progestin 
of the 19-nortestosterone group), and conducted western blotting to validate our ELISA findings. Despite the 
fact that these patients were on therapy, we noticed similar downregulation of TTP and HuR in ectopic lesions 
observed in our patient cohort that did not receive any hormonal therapy for 3 months prior to laparoscopic 
surgery. The rationale behind including this patient subset was to compare whether the anti-inflammatory effects 
of Dienogest would have an impact on HuR/TTP axis deficiencies observed in our patients with no hormonal 
therapy. Previous studies by Karipcin et al.28 have shown decreased HuR expression in mid-late proliferative and 
early-mid secretory phases in ectopic lesions from their endometriosis patient cohort. Nevertheless, findings 
from both of our patient cohorts display dysregulation of HuR/TTP axis, suggesting that the anti-inflammatory 
effects of Dienogest are independent of the axis29. The ratio of mRNA stabilizers/destabilizers may be mediated 
by the menstrual cycle and different ovarian hormones, and aberrations in this ratio may provide cellular survival 
advantage to the ectopic endometrial lesion. In comparison to findings by Karipcin et al.28, further studies will 
need to be performed to examine HuR/TTP axis throughout the menstrual cycle.
Additionally, our in vitro TTP knockdown downstream protein results support this association since TNF-α 
was found to be elevated in the endometrial epithelial cells and differed at the mRNA level. Importantly, HuR/
TTP axis ratio changes are distinctly different in 12Z endometriotic cells compared to non-endometriotic EECC 
cells. Downregulation of TTP via siRNA in EECCs caused all other RNA binding proteins examined, including 
Figure 6. TTP knockdown results in distinct endometriotic (12Z) and endometrial epithelial (EECC)-specific 
inflammatory profiles: In vitro downstream mRNA analysis of inflammatory cytokines associated with RNA 
binding protein regulation in TTP knockdown EECCs and 12Zs. Transcripts for IL-6, TNF-α, HIF-1α were 
downregulated in EECC cells treated with TTP siRNA (Panels A,B,D) compared to scrambled controls. 
Transcripts for COX-2, GM-CSF, and IL-10 do not differ in TTP knockdown EECCs (Panels C,E,F). On the 
other hand, TTP knockdown results in upregulation of COX-2, HIF-1α and GM-CSF in endometriotic epithelial 
12Z cells treated with TTP siRNA compared to scrambled controls (Panels I–K). Transcripts for IL-6, TNF-α, 
and IL-10 do not differ in TTP knockdown 12Zs (Panels G,H,L). Expression data illustrated as mean ± SEM. 
*P < 0.05. Each group (treated and control) consisted of three wells performed in triplicates. Data is derived 
from three independent experiments; n = 3.
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Figure 7. TTP knockdown results in higher levels of TNF-α cytokine: In vitro downstream protein analysis of 
inflammatory cytokines associated with RNA binding protein regulation in TTP knockdown EECCs. Although 
mRNA transcripts of TNF-α was significantly higher in control EECCs compared to TTP knockdown cells, the 
opposite was observed at the protein level using multiplexing (Panel A). Other inflammatory cytokines for IFN-
γ, IL-6, IL-12(p70), IL-8 and GM-CSF did not differ at protein level (Panels B–F). Expression data illustrated as 
mean ± SEM. *P < 0.05. Data is derived from three independent experiments; n = 3.
Figure 8. HuR and TTP is immunolocalized throughout the endometrial microenvironment in eutopic 
and ectopic endometrium from a mouse model of endometriosis. HuR localization patterns were examined 
in eutopic (Panels A,B) and ectopic (Panels C,D) endometrium. HuR immunostaining was primarily found 
in glandular epithelium (blue arrows; brown staining prominent in panels A), and endometrial stroma (red 
arrows, Panels A,C) from both eutopic and ectopic endometrium TTP was localized primarily in glandular 
epithelium (blue arrows; Panel A), endometrial epithelium and luminal epithelium (green arrows; prominent 
staining in Panel E compared to isotype negative in Panel F) in eutopic endometrium. High levels of TTP 
immunolocalization was noted in endometrial stroma in ectopic lesions (Panel G compared to isotype negative 
Panel H). Images are representative of 5 slides from 6 mice from 2 experiments (n = 3 day 7, n = 3 day 17). 
Panels A,B original magnification, 100X, scale bar: 75 µm. Panels C,D,G,H original magnification, scale bar: 
300 µm 200X, Panels E,F original magnification, 40X, scale bar: 300 µm.
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HuR, to decrease in expression. Conversely, in TTP downregulated endometriotic 12Z cells, HuR as well as other 
TIS11 family of RNA binding proteins were upregulated. This endometriosis-specific change in HuR/TTP ratio in 
the 12Z cells may be due to chronic inflammatory milieu these cells originally were exposed and present in them. 
Indeed, previous findings have pointed to a unique endometrial microenvironment in endometriosis patients that 
contain signature molecular changes, in part due to chronic inflammation persisting in the peritoneal cavity of 
these women9, 30, 31. Our target inflammatory cytokine profiling in TTP knockdown cells and mRNA findings in 
these same cells yielded contrasting findings. Inflammatory cytokines IL-6 and TNF-α mRNA was significantly 
higher in control group compared to TTP knockdown EECCs. The opposite effect has been noted for IL-6 in 
embryonic fibroblasts from TTP-deficient mice32 as well as TNF-α and in TTP-silenced macrophages33. This 
opposite effect was also observed between protein and mRNA for TTP’s major known target, TNF-α and no 
observed changes were noted for IL-6, which suggests to us that other posttranscriptional regulation may be at 
play in the endometrium. Additionally, HIF-1α transcripts were significantly lower in TTP knockdown EECCs, 
however COX-2, an inducer of HIF-1α does not differ and although not statistically different, is expressed at mod-
erately higher at mRNA levels in the same treated group compared to controls. Recent studies have established 
links between microRNAs as well as other regulators (lncRNAs, PIWI, etc.) and RNA binding proteins includ-
ing both TTP and HuR. Specifically, TTP has been shown to promote the microRNA let-7 via down-regulation 
of Lin28 mRNA and down-regulation of let-7 in serum of mice with endometriosis shows implication of this 
microRNA in endometriosis34, 35. The microRNA miR-29a has also been shown to suppress TTP36 and our recent 
data also suggest that miR-29c contributes to progesterone resistance in endometriosis37. These unique interac-
tions may be contributing to this aberrant change in expression38, although we do not discount other forms of 
regulation (i.e. hormonal) occurring as well.
Tissue-wide profiling experiments examining TTP family mRNA expression have shown moderate to high 
expression levels of TTP family members in the female reproductive tract, including the ovary20. Additionally, 
HuR has been previously shown to be localized throughout the epithelium of eutopic and ectopic endometriotic 
lesions, with specific primary localization occurring in the nucleus28. We sought to obtain a basic understanding 
of TTP and HuR localization patterns using our syngeneic mouse model of endometriosis in order to compare 
and contrast to the aforementioned findings. Indeed, we found similar localization patterns to those previously 
documented in the normal eutopic endometrium and found that both of these important RNABPs are localized 
throughout the ectopic endometrial lesions as well. This finding is encouraging and further supports the physi-
ological relevance of these RNABPs in the context of endometriosis and other female reproductive pathologies. 
Future studies in the mouse model will be useful to determine if modulation of HuR/TTP axis would impact 
endometriotic lesion growth and survival.
Overall, our findings suggest that the HuR/TTP axis of RNA binding proteins should be examined together 
as a ratio, rather than individually. In this study, we have shown that aberrations in the ratio of the HuR/TTP 
axis can cause molecular differences in both endometriotic as well as non-endometriotic endometrial epithe-
lial choriocarcinoma cells. This leads us to believe that aberrations in the ratio of HuR/TTP axis can also have 
similar molecular changes in the local peritoneal microenvironment. Our in vitro TTP knockdown experiments 
demonstrate that RNABPs are regulated in the absence of ZFP36, although the exact mechanisms have yet to be 
determined. These studies also point toward the existence of a functional role of TTP/ZFP36 in endometriotic 
epithelial 12Z and EECCs. Limitations in our study include limited sample sizes of patients, which did not allow 
us to further group our patient data sets by stage of disease, although most of these patients were classified as hav-
ing early stage (I-II) of endometriosis. We also acknowledge the fact that the TTP/ZFP36 knockdown mechanistic 
experiments were performed only using an in vitro approach. Future studies will aim to recapitulate these findings 
in an in vivo model and to examine which exact mechanisms are influencing the HuR/TTP axis environment in 
unique subsets of endometriosis patients.
To the best of our knowledge, this work is the first to categorize the HuR/TTP axis in the context of chronic 
inflammation in endometriosis patients compared to menstrual stage matched fertile controls. We used matched 
ectopic and eutopic endometrial biopsies to see understand changes in the same patient subset. Overall we 
demonstrate that: 1) Differential expression of TTP and HuR at the site of the ectopic endometriotic lesion and 
eutopic endometrium in women, further supported by data from our mouse model of endometriosis. 2) RNA 
binding proteins are regulated in the absence of TTP/ZFP36. 3) Unique endometriosis-specific inflammatory 
cytokine expression profiles in TTP knockdown endometriotic 12Z and EECCs. Although speculative, our data 
suggest that the HuR/TTP axis likely works in combination with specific microRNAs and lncRNAs to regulate 
inflammation both at the site of the ectopic lesion and in the local peritoneal microenvironment. Future work will 
aim to pinpoint mechanisms of HuR/TTP axis in direct destabilization of inflammatory cytokines at the site of 
the endometriotic lesions using reporter assays.
Methods
Ethics approval. Ethics approval for this study was provided by the Health Sciences Research Ethics 
Board, Queen’s University, Kingston, Ontario, Canada. Human ectopic endometriosis as well as eutopic endo-
metrial tissue samples were collected from patients with endometriosis as per approved protocols and guide-
lines. Additionally, endometrial samples were collected from control subjects comprising healthy women after 
informed consent with the use of a protocol approved by the Institutional Review Committees at Greenville 
Health Systems, Greenville, South Carolina, and the University of North Carolina, Chapel Hill, North Carolina 
(IRB protocol number. Pro00000993). All methods were performed as per institutional approved guidelines.
Sample collection from endometriosis patients and control women. Matched human endome-
trium (n = 22) and endometriotic lesions (n = 22) from endometriosis patients were provided by Greenville 
Hospital Systems, Greenville, South Carolina, upon informed consent. Patient samples were further grouped 
www.nature.com/scientificreports/
1 0Scientific RepoRts | 7: 5883  | DOI:10.1038/s41598-017-06081-7
into two groups: early stage I-II (n = 13), and advanced stage III-IV (n = 9). Eutopic endometrium samples were 
obtained by Pipelle sampling during time of laparoscopic surgery for removal of endometriotic lesions. The 
patient samples used in this study from Greenville Hospital were comprised of women previously diagnosed with 
infertility and/or pelvic pain. Both patients and fertile control subjects from Greenville Hospital were free from 
hormonal therapy for 3 months before the collection of samples. The stage of endometriosis was determined 
based on the revised American Society of Reproductive Medicine criteria39. For control samples, endometrial 
biopsies (n = 16) were obtained by means of Pipelle sampling from healthy fertile women who underwent tubal 
ligation at the University of North Carolina. All sixteen healthy control subjects had no signs or symptoms of 
endometriosis or fertility problems and history of pregnancy. All patients and healthy control subjects were at 
the secretory phase of the menstrual cycle when samples were obtained. Samples obtained were snap-frozen with 
the use of liquid nitrogen and then stored at −80 °C until further use. Patient samples from The Ottawa Hospital 
used for Western blotting studies comprised of matched human endometrium (n = 8) and endometriosis samples 
(n = 8) from endometriosis patients. These patients samples comprised of women diagnosed with infertility and/
or pelvic pain and were receiving Dienogest before collection of samples.
Mouse model of endometriosis. BALB/cByJ mice (n = 8) (Jackson Laboratory, USA) were housed in 
cages of 3–4 mice. All animal experiments were performed under Canadian Council of Animal Care guidelines 
and protocols approved by Queen’s University Institutional Animal Care Committee (Protocol number 2013–
061). Donor mice (n = 2) were sacrificed, uterine horns removed, and placed in a Petri dish containing PBS. The 
endometrium was separated from myometrium, cut into 1 mm3 segments, washed in PBS, and kept on ice until 
surgically implanted in mice. Prior to surgery, recipient mice were anesthetized with 3% isofluorane vaporizer. 
Small incisions were made in the abdomens of recipient mice and donor mouse endometrium were placed into 
the left side of the peritoneal cavity of recipient mice using bonding agent. All recipient mice were sacrificed at 
Days 7 (n = 3) and 17 (n = 3) following surgery. Ectopic lesions were removed and stored in 4% paraformaldehyde 
prior to tissue processing.
In vitro downregulation of TTP in 12Z and endometrial carcinoma cell lines. Silencing of TTP was 
performed using a siRNA-based approach in EECC and 12Z cells. In these experiments, EECCs represent gener-
alized epithelial phenotype, while 12Z cells represent epithelium from the endometriotic lesions. Briefly, 200,000 
cells were plated in 6 well plates (Sarstedt AG, Germany) in antibiotic-free Dulbecco’s medium (F-10 EECCs, F12 
12Z) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich, Canada). The 12Z cells were grown as 
per previously published protocol40. Briefly, 12Z cells had addition of 1% sodium pyruvate in the DMEM media 
and were previously checked for absence of mycoplasma. Cells were grown for 18 hours until 60% confluence 
and transfected with 1 µg of TTP duplex siRNA (sc-36760, Santa Cruz Biotechnology, Texas, USA) mixed with 
8 ul of siRNA transfection reagent and 200 ul siRNA transfection medium (sc-29528 & sc-36868, Santa Cruz 
Biotechnology, Texas, USA). Scrambled control siRNA (sc-37007, Santa Cruz Biotechnology, Texas, USA) were 
added to control wells. Cells were incubated for 8 hours at 37 °C and DMEM supplemented with 20% FBS was 
added and incubated for an additional 24 hours. Medium was aspirated followed by supernatant collection and 
all cells were collected for downstream applications (RNA and protein extraction). Knockdown efficiency of TTP 
was determined using qPCR and western blotting approaches and knockdown efficiency cut-off threshold was 
set at 70%.
RNA binding protein mRNA detection using quantitative real-time PCR. The mRNA of TTP fam-
ily as well as the mRNA stabilizer, ELAVL1 were assessed using quantitative real-time PCR (qPCR). Total RNA 
from endometriosis, eutopic endometrium patient and control samples as well as cell lysates from 12Z and EECC 
cultures were reverse transcribed using Superscript II reverse transcription kit (Life Technologies, Canada) as per 
the manufacturer’s protocol. Primers (Table 1) were designed using Primer3 software (http://frodo.wi.mit.edu/
primer3/) from murine and human sequences available on NCBI’s Nucleotide. Real-time PCR was performed 
using plate-based LC-480 (Roche Diagnostics., Montreal, Canada). Experimental set-up was according to the 
MIQE guidelines41. Relative quantification was performed using ACTB as a control gene. Pooled human endo-
metrial and murine cDNA was used as calibrators. Expression of ACTB did not differ across groups by one-way 
ANOVA. All samples were run in triplicates. The run protocol for all genes of interest used was the following: 
Denaturation: 95 °C, 15 min; Amplification: 45 cycles: 95 °C for 15 s, 55 °C for 30 s, 70 °C for 30 s; Melting Curve: 
70–95 °C, at a rate of 0.1 °C per second. Data was analyzed using the ∆∆Ct method.
TTP and HuR ELISA Assay. Total protein was extracted from eutopic (n = 22) and ectopic endometrium 
(n = 22). Approximately 20 mg of tissue placed in 1.5 mL microcentrifuge tube containing 0.3 g/mL of protease 
inhibitor cocktail (Sigma-Aldrich, Canada), in 200 µL of PBS. Upon tissue homogenization, samples were cen-
trifuged at 4 °C and supernatant was collected. Protein concentrations were determined using a bicinchoninic 
acid (BCA) assay (Thermo-Fisher Scientific, Canada) as per kit manufacturer’s instructions. Eutopic and ectopic 
endometrium protein obtained from endometriosis patients were thawed at room temperature. TTP and HuR 
were quantified using TTP and HuR immunoassay kits following manufacturer’s protocol (Cat #MBS2602738 
and MBS919324, MyBioSource Inc., CA, USA). Briefly, samples were added to 96-well immunoassay plates 
pre-coated with antihuman TTP and HuR antibodies and following incubation, absorbance was read at 450 nm 
within 15 mins using SpectraMAX Plus spectrophotometer (Molecular Devices, USA). Sensitivity for TTP and 
HuR immunoassays were 60.00 and 6.25 pg/ml, respectively.
Western Blotting. TTP and HuR protein expression in ectopic compared to eutopic endometrium from 
endometriosis patients from Ottawa Hospital cohort was determined using western blotting. Total protein was 
extracted from eutopic (n = 8) and ectopic endometrium (n = 8). Approximately 20 mg of tissue placed in 1.5 mL 
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microcentrifuge tube containing 0.3 g/mL of protease inhibitor cocktail (Sigma-Aldrich, Canada), in 200 µL of 
PBS. Upon tissue homogenization, samples were centrifuged at 4 °C and supernatant was collected. Protein con-
centrations were determined using a bicinchoninic acid (BCA) assay (Thermo-Fisher Scientific, Canada) as per 
kit manufacturer’s instructions. All samples were normalized to a protein concentration of 10 µg/µL using PBS 
and stored at −80 °C. Samples were denatured at 99.9 °C for 5 minutes in a thermal cycler (Bio-Rad, CA, USA). 
5 ul of loading dye was pipetted to appropriate wells of 12% Tris-glycine pre-cast gels (Bio-Rad, CA, USA) (12 
wells/20 µL) and separated at 120 V for approximately 1 h. Transferring was performed onto PVDF membranes 
(Thermo-Fisher Scientific, Canada) and run at 100 V for 2 h. Membranes were blocked in 5% skim milk TBS-T 
solution overnight. 1 µg/mL of Rabbit polyclonal anti-TTP/ZFP36 (Ab83579, Abcam, CA, USA) and 1.0 µg/
mL Rabbit monoclonal anti-HuR/ELAVL1 (Abcam Ab200342) antibodies were added as primary antibodies. 
Membranes were rinsed 3 X at 10 mins with TBS-T solution and 5 X at 5 mins with TBS solution. HRP conjugated 
goat anti-rabbit IgG 1:2000 (R&D, HAF008), secondary antibody was added in 5% skim milk TBS-T solution 
to each of the membranes and incubated on a rocker at room temperature (RT) for 2 h. Enhanced chemilumi-
nescence detection was completed with Clarity chemiluminescent substrate solution (Abcam, CA, USA) and 
imaged on a Kodak X-ray film processor. Membranes were stripped and re-probed for ACTB using 1.5 µg/mL of 
anti-ACTB mouse monoclonal antibody (Ab20272, Abcam, CA, USA) diluted with 5% skim milk TBS-T solu-
tion, and incubated on an electric plate-rocker in a 4 °C refrigerator for 12 h. All films were scanned on a flatbed 
scanner at 600dpi greyscale and images were analyzed using ImageJ software (NIH, Bethesda, MD) to obtain 
densitometry values.
Multiplex cytokine analysis. A 12-plex high sensitivity commercial available multiplex assay was con-
ducted from Eve Technologies, Calgary, Alberta using Luminex xMAP laser bead platform (Bio-Rad, CA, 
USA). This multiplex assay was customized to cytokines involved in inflammation/inflammatory pathways, and 
included: GM-CSF, IFNγ, IL-1B, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17, IL-23, TNF-α. Briefly, color-coded 
polystyrene beads were coupled with capture antibodies for each cytokine. A total of 50 µl of each protein samples 
were aliquoted and normalized. The normalized protein samples were incubated in a mixture containing the 
Gene Name Primer Product Size (bp) GenBank Accession Number
mZfp36
for: 5′-CTCCTGCCGAAGGTCTACTA-3′
155 NM_011756
rev: 5′-TGCCTCAAAGACAGGTGAGTC-3′
mZfp36l1
for: 5′-CAAGGGTAACAAGATGCTCAACTAC-3′
222 NM_007564
rev: 5′-GAGAAAGAGCGGTCTCGAAAG-3′
mZfp36l2
for: 5′-GCTGCCACCTCCCTAAACTA-3′
190 NM_001001806
rev: 5′-GCAATGAGCCCGTTATCA-3′
mElavl1
for: 5′-GGCTGGTGCATCTTCATCTAC-3′
176 NM_010485
rev: 5′-GCCATTGCAGCTTCTTCATAGT-3′
hZFP36
for: 5′-CATGGATCTGACTGCCATCTA-3′
279 NM_003407.3
rev: 5′-GAAGTGGGTGAGGGTGACAG-3′
hZFP36L1
for: 5′-TCTGCCACCATCTTCGACTT-3′
109 BT019468.1
rev: 5′-TGCCCACTGCCTTTCTGT-3′
hZFP36L2
for: 5′-ACTCCGATGAGTTTGGGACTT-3′
251 NM_006887.4
rev: 5′-ATGGGCTGAGGGCTAACTATC-3′
hELAVL1
for: 5′-GTTCAGCAGCATTGGTGAAGT-3′
253 BT009793.1
rev: 5′-TTCTACGTCCTTCTGGGTCAT-3′
hCOX-2
for: 5′-ATGTTCCACCCGCAGTACA-3′
202 NM_000963.3
rev: 5′-TTCTACCAGAAGGGCAGGATAC-3′
hIL-6
for: 5′-CCAGAGCTGTCCAGATGAGTA-3′
206 M14584.1
rev: 5′-TGAGGTGCCCATGCTACA-3′
hTNF-α
for: 5′-CCAGTCTGGGCAGGTCTACT-3′
205 M26331.1
rev: 5′-GGTTTCGAAGTGGTGGTCTT-3′
hGM-CSF
for: 5′-TGAAGGACTTTCTGCTTGTCAT-3′
225 NM_000758.3
rev: 5′-TCTTCTGCCATGCCTGTATC-3′
hIL-10 for: 5′-GGCACCCAGTCTGAGAACA-3′  rev: 5′-GCATCACCTCCTCCAGGTAAA-3′ 220 M57627.1
hHIF-1α
for: 5′-CCATTCCTCACCCATCAAATA-3′
254 AB733094.1
rev: 5′-TTTGGCAAGCATCCTGTACT-3′
mActb
for: 5′-GGCTGTGCTGTCCCTGTATG-3′
272 NM_007393.5
rev: 5′-CCATCTCCTGCTCGAAGTCTA-3′
hACTB
for: 5′-GAGGCCTGGACTCTCAACTG-3′
187 AY582799.1
rev: 5′-AATGAATGGGGGTTGAATGA-3′
Table 1. mRNAs Assessed by Real-Time PCR.
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capture antibodies conjugated to magnetic beads in a custom 96-well plate. The plate was incubated in a dark 
room on a shaker at room temperature for 30 mins. The plate was washed three times with wash buffer. Detection 
antibody (25 μL) was added with antibody diluent and incubated in the dark on a shaker at RT for 30 mins. Upon 
rinsing three times with wash buffer, 50 μL streptavidin-phycoerythrin fluorescent conjugate was added to all 
wells. The plate was incubated for 10 mins and washed and loaded. The standards for this assay were provided by 
the manufacturer as a lyophilized cocktail of proteins and run for each individual target analyte. Standard curve 
dilutions were run on the assay. Increasing fluorescent intensity signals were read as fluorescence intensity (FI) 
values, which correspond to protein bound to each analyte bead. The observed concentration (OC) for each target 
analyte was calculated against standard curve regression.
Immunohistochemical localization of TTP and HuR in endometriotic lesions from mouse 
model. Ectopic endometriotic lesion (n = 3) and eutopic endometrium (n = 3) were embedded in paraffin 
and cut (5 µm) and mounted on charged slides (Superfrost, Thermoscientific, Canada). Paraffin-embedded endo-
metrium were used for TTP and HuR immunolocalization experiments using previously published IHC proto-
col25. Briefly, antigen retrieval was performed with citric acid buffer boiling for 2 mins. Blocking was performed 
on all sections using 1% bovine serum albumin (BSA) for 1.5 hours at room temperature. Rabbit polyclonal to 
tristetraprolin (sc-12563, Santa Cruz Biotechnology, USA) and Rabbit monoclonal anti-HuR (ab200342, Abcam 
plc., UK) were added at 1.5 µg/mL and 0.8 µg/mL, respectively. Biotin-conjugated secondary antibody was used 
(K0690, DakoCytomation, USA) was added to all sections and incubated for 45 mins at room temperature. DAB 
was utilized as chromogen and was controlled for 10 seconds and 15 seconds per section for TTP and HuR, 
respectively. Counterstaining was done using haematoxylin for 15 seconds and upon rinsing, slides were dehy-
drated and coverslips were added. All slide images were taken using a ZEISS observer microscope and analyzed 
using ZEISS imaging software (Zeiss, Canada).
Statistical Analysis. In vivo patient mRNA and protein data were analyzed by one-way analysis of vari-
ance (ANOVA). Patient outliers were removed using ROUT outlier removal from Graphpad Prism 6.05 software 
(Q = 5%). Mouse model data were analyzed using parametric paired t-test. The in vitro silencing experiments 
used an unpaired Student’s t-test. A p < 0.05 was considered as statistically significant.
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